Mr. Rakesh underwent a total of six cycles of the R-EPOCH chemotherapy regimen, followed by three cycles of the R-GDP regimen, and subsequently received two additional cycles of the same regimen. This intensive chemotherapy regimen occurred from April 2018 to October 2019, marked by perseverance and resilience amid challenges.
During the October 2019 PET-CT re-evaluation, new metabolic irregularities were identified in the right calcaneus and the right distal femur, despite the challenging treatment regimen. Mr. Rakesh pursued the expertise of a hospital in Beijing, recognizing it as the leading CAR-T center worldwide.
In November 2019, Mr. Rakesh initiated a new phase of treatment with our medical team. Comprehensive examinations indicated dim-positive CD19 and markedly strong positive CD22, suggesting significant residual tumor activity. Based on these findings, the decision was made to implement CD19+CD22 CAR-T cell therapy, an advanced method aimed at addressing the ongoing malignancy.
Post-infusion, Mr. Rakesh exhibited a manageable grade 2 Cytokine Release Syndrome (CRS) and subsequently recovered rapidly. In January 2020, he was discharged following favorable results from a recent PET-CT scan, which indicated tumor regression and a significant reduction in metabolic activity.
Mr. Rakesh’s journey highlights the significant impact of advanced medical interventions in oncology. In initiating a long-term outpatient follow-up regimen, the emphasis is on maintaining the achieved vitality and preventing disease recurrence.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.